Natco Pharma stock faces rights issue decision after 0.15 percent fall

Published on 09/23/2026 at 09:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Natco Pharma stock closed at INR 815.05 on September 22, 2026, down 0.15 percent. June revenue was INR 596.60 crore and profit INR 74.60 crore.

Natco, INE987B01026, Illustration mit AI erstellt.

Natco Pharma stock (ISIN INE987B01026) closed at INR 815.05 on the NSE on September 22, 2026, down INR 1.25, or 0.15 percent, from the previous close. The immediate company event is a board meeting on September 25 to consider a rights issue of up to INR 1,300 crore.

Rights issue sets the near term

NDTV Profit reported on September 23, 2026, that Natco Pharma's board will meet on September 25 to consider a rights issue of up to INR 1,300 crore and its terms. The proposal links the next valuation discussion to capital allocation and potential dilution rather than to a new operating forecast.

The exchange filing identifies September 25, 2026, as the date for the fund-raising discussion, according to NSE India. The amount under consideration is INR 1,300 crore, while the final structure and terms remain the key variables for shareholders.

June figures show lower scale

For June 2026, Natco Pharma reported revenue of INR 596.60 crore, net profit of INR 74.60 crore, EBITDA of INR 154.30 crore and earnings per share of INR 4.17, based on the financial data reported by Bajaj Broking. The same data show a 12.50 percent net margin, giving investors an operating benchmark for the fund-raising decision.

The comparison with March 2026 is uneven: June revenue of INR 596.60 crore was below the March figure of INR 608.80 crore, while June net profit of INR 74.60 crore was below March net profit of INR 209.60 crore. The June quarter therefore provides a weaker earnings base than the preceding quarter, even though EBITDA reached INR 154.30 crore.

Stock remains below yearly high

Natco Pharma's NSE market capitalization was INR 14,620.74 crore on September 22, 2026, according to the quoted market data. Another market snapshot placed the 52-week range at INR 789.00 to INR 1,226.80, putting the September 22 close INR 411.75 below the yearly high and INR 26.05 above the low.

The price action makes the September 25 meeting material for the stock's next comparison point. Investors will have to weigh the proposed INR 1,300 crore capital raise against June revenue of INR 596.60 crore and net profit of INR 74.60 crore, with the final rights terms determining the dilution arithmetic.

September 22 close frames the decision

Natco Pharma stock closed at INR 815.05 on the NSE on September 22, 2026, a level above the reported 52-week low of INR 789.00 and below the 52-week high of INR 1,226.80. The September 25 board meeting is the next dated company checkpoint.